全国爱肝日丨南月敏教授解读指南：丙肝治疗的泛基因型优选方案 ...

参考文献：

[1]中华医学会肝病分会,中华医学会感染病学分会.丙型肝炎防治指南（2019版）[J].中华肝病杂志,2019,27(12):962-979

[2]2019年《国家基本医疗保险、工商保险和生育保险药品目录》

[3]Bourlière M, Pietri O. Hepatitis C virus therapy: no one will be left behind[J]. Int J Antimicrob Agents, 2019, 53(6): 755-760. DOI: 10.1016/j.ijantimicag.2018.12.010.

[4]Wei L, Lim SG, Xie Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(2): 127-134. DOI: 10.1016/S2468-1253(18)30343-1.

[5]索磷布韦维帕他韦片说明书. 核准日期 2018年5月23日.

[6] FDA Warns About Rare Occurrence of Serious Liver Injury with Use of Hepatitis C Medicines Mavyret, Zepatier, and Vosevi in Some Patients with Advanced Liver Disease FDA  Alerts. www.drugs.com <http://www.drugs.com>

[7] Zepatier Evvpreport, MSD Japan. 2017

[8]Mavyret Evvp report, Abbive Japan. 2018